Back to Search

Conference item

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+

Publication status:: Published

Peer review status:: Reviewed (other)

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Govindan, R., Dols, M. C., Aix, S., Postmus, P. E., Lewanski, C., Bennouna, J., Fischer, J., Vidal, O., Stewart, D., Ardizoni, A., Weaver, J., Wolfsteiner, M., Reck, M., Talbot, D., Morgensztern, D., & Ong, T. J. (2017). Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+. Journal of Thoracic Oncology, 12(11, Supplement 2), S1839–S1840.

MLA Style

Govindan, R., et al. “Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2l+.” Journal of Thoracic Oncology, vol. 12, no. 11, Supplement 2, Elsevier, 2017, pp. S1839–S1840.

Chicago Style

Govindan, R, MC Dols, S Aix, PE Postmus, C Lewanski, J Bennouna, J Fischer, et al. 2017. “Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2l+.” In Journal of Thoracic Oncology, 12:S1839–S1840. Elsevier.
Tweet
Print

Access Document

Files:: Govindan.pdf

(Version of record, 292.5KB)

Publisher copy:: 10.1016/j.jtho.2017.09.534

Authors

+ Govindan, R More by this author

Role:

Author

+ Dols, MC More by this author

Role:

Author

+ Aix, S More by this author

Role:

Author

+ Postmus, PE More by this author

Role:

Author

+ Lewanski, C More by this author

Role:

Author

More authors...

Bibliographic Details

Publisher:: Elsevier Publisher's website
Host title:: Journal of Thoracic Oncology
Journal:: Journal of Thoracic Oncology Journal website
Volume:: 12
Issue:: 11, Supplement 2
Pages:: S1839-S1840
Publication date:: 2017-11-07
DOI:: 10.1016/j.jtho.2017.09.534
EISSN:: 1556-1380
ISSN:: 1556-0864

Item Description

Language:: English
Keywords:: nab-paclitaxel

durvalumab

FFR

second-line
Pubs id:: 995977
Local pid:: pubs:995977
Deposit date:: 2020-06-08

Terms of use

Copyright holder:: Elsevier Inc.
Copyright date:: 2017
Rights statement:: Copyright © 2017 Published by Elsevier Inc.

Licence:: CC Attribution (CC BY)

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP